Clinical trials: Early Alzheimers Disease
Alzheimer's Disease
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
This study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid load as measured by positron emission tomography…
- Trial name
- NCT01227564
- Testing
- ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg
- Where
- 40 sites in United States
- Volunteers
- 63 people
- Sponsor
- Pfizer
Alzheimer Disease, Early Onset Alzheimer Disease
Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
This clinical trial is an open label, dose-ranging study designed to evaluate gene therapy to treat patients who are APOE4 homozygotes with clinical diagnosis varying from mild cognitive impairment due to Alzheimer's, mild…
- Trial name
- NCT03634007
- Testing
- LX1001
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Lexeo Therapeutics
Early Alzheimer's Disease
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
The primary objective of the study is to evaluate the effects of hepatic impairment on the pharmacokinetics (PK) of E2609 after a single dose administration.
- Trial name
- NCT02859207
- Testing
- E2609
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick together. This leads to changes in thinking and behaviour.
- Trial name
- PRImus-AD (NCT06182085)
- Testing
- PRI-002
- Where
- 38 sites in Czechia, Germany and 4 more
- Volunteers
- 304 people
- Sponsor
- PRInnovation GmbH
Early-Onset Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with…
- Trial name
- NCT05231785
- Testing
- ALN-APP
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimer Disease
Study of ASN51 in Adults With Early Alzheimer's Disease
The main purpose of this study is to evaluate the safety, tolerability, and effect on biomarkers of disease pathophysiology and pathology, pharmacokinetics (PK), and preliminary effects on measures of clinical efficacy of…
- Trial name
- NCT06677203
- Testing
- ASN51
- Where
- 7 sites in United States
- Volunteers
- 123 people
- Sponsor
- Asceneuron S.A.
Alzheimer Disease, Early Onset
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
- Trial name
- NCT06750432
- Testing
- PMN310
- Where
- 22 sites in United States
- Volunteers
- 144 people
- Sponsor
- ProMis Neurosciences, Inc
Alzheimer Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
- Trial name
- VIVA-MIND (NCT03919162)
- Testing
- PQ912
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Vivoryon Therapeutics N.V.
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Alzheimer Disease, Lymphatic Obstruction
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
The objective of this investigational device exemption (IDE) study is to evaluate the safety and feasibility of using the Symani System and microsurgical techniques in the deep cervical lymph node (dCLN) region in the setting of…
- Trial name
- REMIND (NCT07178210)
- Testing
- Symani Surgical System
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- MMI (Medical Microinstruments, Inc.)
Early Alzheimer's Disease
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD).
- Trial name
- NCT07033494
- Testing
- MK-2214
- Where
- 80 sites in United States, Argentina and 9 more
- Volunteers
- 340 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects
A Randomized, Double-blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Alzheimer's Disease
- Trial name
- NCT03817684
- Testing
- BPN14770
- Where
- 41 sites in United States
- Volunteers
- 255 people
- Sponsor
- Tetra Discovery Partners
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer's Disease
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
Approximately 90 patients, aged 50 to 80 years, with a diagnosis of early Alzheimer's disease will take part in this research study. This study will be conducted in the US.
- Trial name
- EAD501 (NCT05607615)
- Testing
- Hydroxypropyl Beta Cyclodextrin
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Cyclo Therapeutics, Inc.
Alzheimer Disease, Early Onset
Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease
multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate the safety and tolerability, efficacy, and PK of 60 mg AD-35 administered QD during 6 months of double-blind treatment followed by a…
- Trial name
- ROAD (NCT03625401)
- Testing
- AD-35 60mg group
- Where
- 10 sites in United States
- Volunteers
- 55 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Early Alzheimer's Disease
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical…
- Trial name
- Clarity AD (NCT03887455)
- Testing
- Lecanemab IV, Lecanemab SC
- Where
- 247 sites in United States, Australia and 12 more
- Volunteers
- 1,906 people
- Sponsor
- Eisai Inc.
Alzheimers Disease
A Post Authorization Registry Study of Participants Treated With LEQEMBI
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm…
- Trial name
- NCT07762092
- Testing
- No Intervention
- Where
- 17 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes)
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- PAST-US (NCT04937959)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer's Disease
Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease
This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).
- Trial name
- DISCOVER (NCT02925650)
- Testing
- Posiphen
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Annovis Bio Inc.
Cognitive Dysfunction, Lewy Body Disease
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily…
- Conditions
- Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
- Trial name
- NCT07589595
- Testing
- Donanemab
- Where
- 72 sites in United States, Japan and 2 more
- Volunteers
- 350 people
- Sponsor
- Eli Lilly and Company